Adamis Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Adamis Pharmaceuticals has been growing earnings at an average annual rate of 2.1%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 37.7% per year.
Key information
2.1%
Earnings growth rate
35.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | -37.7% |
| Return on equity | n/a |
| Net Margin | -495.1% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Adamis Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 5 | -25 | 15 | 7 |
| 31 Dec 22 | 5 | -26 | 13 | 10 |
| 30 Sep 22 | 1 | -31 | 13 | 12 |
| 30 Jun 22 | 1 | -32 | 15 | 14 |
| 31 Mar 22 | 2 | -31 | 16 | 13 |
| 31 Dec 21 | 2 | -35 | 16 | 11 |
| 30 Sep 21 | 4 | -39 | 24 | 10 |
| 30 Jun 21 | 4 | -43 | 22 | 8 |
| 31 Mar 21 | 0 | -42 | 18 | 8 |
| 31 Dec 20 | 3 | -36 | 20 | 8 |
| 30 Sep 20 | 8 | -28 | 15 | 9 |
| 30 Jun 20 | 13 | -25 | 17 | 10 |
| 31 Mar 20 | 22 | -26 | 23 | 10 |
| 31 Dec 19 | 22 | -28 | 25 | 10 |
| 30 Sep 19 | 21 | -36 | 27 | 16 |
| 30 Jun 19 | 19 | -38 | 28 | 17 |
| 31 Mar 19 | 17 | -40 | 27 | 19 |
| 31 Dec 18 | 15 | -39 | 26 | 19 |
| 30 Sep 18 | 14 | -34 | 25 | 15 |
| 30 Jun 18 | 13 | -32 | 24 | 12 |
| 31 Mar 18 | 13 | -27 | 24 | 8 |
| 31 Dec 17 | 13 | -26 | 23 | 8 |
| 30 Sep 17 | 13 | -18 | 22 | 5 |
| 30 Jun 17 | 11 | -19 | 21 | 6 |
| 31 Mar 17 | 10 | -20 | 20 | 8 |
| 31 Dec 16 | 6 | -21 | 17 | 10 |
| 30 Sep 16 | 4 | -24 | 14 | 9 |
| 30 Jun 16 | 2 | -19 | 11 | 9 |
| 31 Mar 16 | 0 | -17 | 9 | 7 |
| 31 Dec 15 | 0 | -14 | 9 | 5 |
| 30 Sep 15 | 0 | -14 | 9 | 5 |
| 30 Jun 15 | 0 | -13 | 9 | 4 |
| 31 Mar 15 | 0 | -12 | 7 | 5 |
| 31 Dec 14 | 0 | -11 | 6 | 4 |
| 30 Sep 14 | 0 | -12 | 4 | 3 |
| 30 Jun 14 | 0 | -10 | 4 | 3 |
| 31 Mar 14 | 0 | -8 | 3 | 1 |
| 31 Dec 13 | 0 | -8 | 2 | 1 |
| 30 Sep 13 | 0 | -5 | 2 | 1 |
| 30 Jun 13 | 0 | -5 | 2 | 1 |
| 31 Mar 13 | 0 | -7 | 2 | 1 |
| 31 Dec 12 | 0 | -7 | 2 | 2 |
Quality Earnings: CY3 is currently unprofitable.
Growing Profit Margin: CY3 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CY3 is unprofitable, but has reduced losses over the past 5 years at a rate of 2.1% per year.
Accelerating Growth: Unable to compare CY3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CY3 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: CY3's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.